Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS)
Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side e...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
N Razazian [verfasserIn] M Maaref [verfasserIn] M Rezaei [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Persisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Armaghane Danesh Bimonthly Journal - Yasuj University Of Medical Sciences, 2016, 25(2020), 2, Seite 148-161 |
|---|---|
| Übergeordnetes Werk: |
volume:25 ; year:2020 ; number:2 ; pages:148-161 |
| Links: |
|---|
| Katalog-ID: |
DOAJ006716911 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ006716911 | ||
| 003 | DE-627 | ||
| 005 | 20230307023916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||per c | ||
| 035 | |a (DE-627)DOAJ006716911 | ||
| 035 | |a (DE-599)DOAJa67eaf6b9022448ebc34bb6eb8cd29c2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a per | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a N Razazian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence. | ||
| 650 | 4 | |a fingolimod | |
| 650 | 4 | |a multiple sclerosis reference | |
| 650 | 4 | |a complications | |
| 650 | 4 | |a disability | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a M Maaref |e verfasserin |4 aut | |
| 700 | 0 | |a M Rezaei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Armaghane Danesh Bimonthly Journal |d Yasuj University Of Medical Sciences, 2016 |g 25(2020), 2, Seite 148-161 |w (DE-627)1760628263 |x 17286514 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2020 |g number:2 |g pages:148-161 |
| 856 | 4 | 0 | |u https://doaj.org/article/a67eaf6b9022448ebc34bb6eb8cd29c2 |z kostenfrei |
| 856 | 4 | 0 | |u http://armaghanj.yums.ac.ir/article-1-2485-en.html |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1728-6514 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1728-6514 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2020 |e 2 |h 148-161 | ||
| author_variant |
n r nr m m mm m r mr |
|---|---|
| matchkey_str |
article:17286514:2020----::vlainfhefcadrgiefetofnoioiteyaflouoptetwtrc |
| hierarchy_sort_str |
2020 |
| callnumber-subject-code |
R |
| publishDate |
2020 |
| allfields |
(DE-627)DOAJ006716911 (DE-599)DOAJa67eaf6b9022448ebc34bb6eb8cd29c2 DE-627 ger DE-627 rakwb per R5-920 N Razazian verfasserin aut Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence. fingolimod multiple sclerosis reference complications disability Medicine (General) M Maaref verfasserin aut M Rezaei verfasserin aut In Armaghane Danesh Bimonthly Journal Yasuj University Of Medical Sciences, 2016 25(2020), 2, Seite 148-161 (DE-627)1760628263 17286514 nnns volume:25 year:2020 number:2 pages:148-161 https://doaj.org/article/a67eaf6b9022448ebc34bb6eb8cd29c2 kostenfrei http://armaghanj.yums.ac.ir/article-1-2485-en.html kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 25 2020 2 148-161 |
| spelling |
(DE-627)DOAJ006716911 (DE-599)DOAJa67eaf6b9022448ebc34bb6eb8cd29c2 DE-627 ger DE-627 rakwb per R5-920 N Razazian verfasserin aut Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence. fingolimod multiple sclerosis reference complications disability Medicine (General) M Maaref verfasserin aut M Rezaei verfasserin aut In Armaghane Danesh Bimonthly Journal Yasuj University Of Medical Sciences, 2016 25(2020), 2, Seite 148-161 (DE-627)1760628263 17286514 nnns volume:25 year:2020 number:2 pages:148-161 https://doaj.org/article/a67eaf6b9022448ebc34bb6eb8cd29c2 kostenfrei http://armaghanj.yums.ac.ir/article-1-2485-en.html kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 25 2020 2 148-161 |
| allfields_unstemmed |
(DE-627)DOAJ006716911 (DE-599)DOAJa67eaf6b9022448ebc34bb6eb8cd29c2 DE-627 ger DE-627 rakwb per R5-920 N Razazian verfasserin aut Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence. fingolimod multiple sclerosis reference complications disability Medicine (General) M Maaref verfasserin aut M Rezaei verfasserin aut In Armaghane Danesh Bimonthly Journal Yasuj University Of Medical Sciences, 2016 25(2020), 2, Seite 148-161 (DE-627)1760628263 17286514 nnns volume:25 year:2020 number:2 pages:148-161 https://doaj.org/article/a67eaf6b9022448ebc34bb6eb8cd29c2 kostenfrei http://armaghanj.yums.ac.ir/article-1-2485-en.html kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 25 2020 2 148-161 |
| allfieldsGer |
(DE-627)DOAJ006716911 (DE-599)DOAJa67eaf6b9022448ebc34bb6eb8cd29c2 DE-627 ger DE-627 rakwb per R5-920 N Razazian verfasserin aut Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence. fingolimod multiple sclerosis reference complications disability Medicine (General) M Maaref verfasserin aut M Rezaei verfasserin aut In Armaghane Danesh Bimonthly Journal Yasuj University Of Medical Sciences, 2016 25(2020), 2, Seite 148-161 (DE-627)1760628263 17286514 nnns volume:25 year:2020 number:2 pages:148-161 https://doaj.org/article/a67eaf6b9022448ebc34bb6eb8cd29c2 kostenfrei http://armaghanj.yums.ac.ir/article-1-2485-en.html kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 25 2020 2 148-161 |
| allfieldsSound |
(DE-627)DOAJ006716911 (DE-599)DOAJa67eaf6b9022448ebc34bb6eb8cd29c2 DE-627 ger DE-627 rakwb per R5-920 N Razazian verfasserin aut Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence. fingolimod multiple sclerosis reference complications disability Medicine (General) M Maaref verfasserin aut M Rezaei verfasserin aut In Armaghane Danesh Bimonthly Journal Yasuj University Of Medical Sciences, 2016 25(2020), 2, Seite 148-161 (DE-627)1760628263 17286514 nnns volume:25 year:2020 number:2 pages:148-161 https://doaj.org/article/a67eaf6b9022448ebc34bb6eb8cd29c2 kostenfrei http://armaghanj.yums.ac.ir/article-1-2485-en.html kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei https://doaj.org/toc/1728-6514 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 25 2020 2 148-161 |
| language |
Persian |
| source |
In Armaghane Danesh Bimonthly Journal 25(2020), 2, Seite 148-161 volume:25 year:2020 number:2 pages:148-161 |
| sourceStr |
In Armaghane Danesh Bimonthly Journal 25(2020), 2, Seite 148-161 volume:25 year:2020 number:2 pages:148-161 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
fingolimod multiple sclerosis reference complications disability Medicine (General) |
| isfreeaccess_bool |
true |
| container_title |
Armaghane Danesh Bimonthly Journal |
| authorswithroles_txt_mv |
N Razazian @@aut@@ M Maaref @@aut@@ M Rezaei @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
1760628263 |
| id |
DOAJ006716911 |
| language_de |
persisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006716911</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307023916.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx |||||o 00| ||per c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006716911</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa67eaf6b9022448ebc34bb6eb8cd29c2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">per</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N Razazian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fingolimod</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple sclerosis reference</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">complications</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">disability</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M Maaref</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M Rezaei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Armaghane Danesh Bimonthly Journal</subfield><subfield code="d">Yasuj University Of Medical Sciences, 2016</subfield><subfield code="g">25(2020), 2, Seite 148-161</subfield><subfield code="w">(DE-627)1760628263</subfield><subfield code="x">17286514</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:148-161</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a67eaf6b9022448ebc34bb6eb8cd29c2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://armaghanj.yums.ac.ir/article-1-2485-en.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-6514</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-6514</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">148-161</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
N Razazian |
| spellingShingle |
N Razazian misc R5-920 misc fingolimod misc multiple sclerosis reference misc complications misc disability misc Medicine (General) Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) |
| authorStr |
N Razazian |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760628263 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
R5-920 |
| illustrated |
Not Illustrated |
| issn |
17286514 |
| topic_title |
R5-920 Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) fingolimod multiple sclerosis reference complications disability |
| topic |
misc R5-920 misc fingolimod misc multiple sclerosis reference misc complications misc disability misc Medicine (General) |
| topic_unstemmed |
misc R5-920 misc fingolimod misc multiple sclerosis reference misc complications misc disability misc Medicine (General) |
| topic_browse |
misc R5-920 misc fingolimod misc multiple sclerosis reference misc complications misc disability misc Medicine (General) |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Armaghane Danesh Bimonthly Journal |
| hierarchy_parent_id |
1760628263 |
| hierarchy_top_title |
Armaghane Danesh Bimonthly Journal |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760628263 |
| title |
Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) |
| ctrlnum |
(DE-627)DOAJ006716911 (DE-599)DOAJa67eaf6b9022448ebc34bb6eb8cd29c2 |
| title_full |
Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) |
| author_sort |
N Razazian |
| journal |
Armaghane Danesh Bimonthly Journal |
| journalStr |
Armaghane Danesh Bimonthly Journal |
| callnumber-first-code |
R |
| lang_code |
per |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
148 |
| author_browse |
N Razazian M Maaref M Rezaei |
| container_volume |
25 |
| class |
R5-920 |
| format_se |
Elektronische Aufsätze |
| author-letter |
N Razazian |
| author2-role |
verfasserin |
| title_sort |
evaluation of the effect and drug side effects of fingolimod in the 3-year follow-up of patients with recurrent form of multiple sclerosis (rrms) |
| callnumber |
R5-920 |
| title_auth |
Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) |
| abstract |
Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence. |
| abstractGer |
Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence. |
| abstract_unstemmed |
Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
2 |
| title_short |
Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS) |
| url |
https://doaj.org/article/a67eaf6b9022448ebc34bb6eb8cd29c2 http://armaghanj.yums.ac.ir/article-1-2485-en.html https://doaj.org/toc/1728-6514 |
| remote_bool |
true |
| author2 |
M Maaref M Rezaei |
| author2Str |
M Maaref M Rezaei |
| ppnlink |
1760628263 |
| callnumber-subject |
R - General Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
R5-920 |
| up_date |
2024-07-03T22:32:37.595Z |
| _version_ |
1803598910035329024 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006716911</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307023916.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx |||||o 00| ||per c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006716911</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa67eaf6b9022448ebc34bb6eb8cd29c2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">per</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N Razazian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract: Background & aim: Fingolimod was the first oral drug in the treatment of multiple sclerosis in its recurrent form, which was approved in 2013 in Iran and has made patients better tolerant to treatment. The aim of the present study was to evaluate the efficacy and pharmacological side effects of Fingolimod in the follow-up of 3-year-old patients with multiple sclerosis. Methods: The present study was a clinical trial. The study population included 28 patients with RRMS disease referred to the clinic of Imam Reza (AS) Hospital in Kermanshah. The patients took one oral capsule of Fingolimod daily for 36 months, and in the three-month period for 36 months after the onset of Fingolimod in terms of recurrence, progression of disability, and possible side effects of the drug were examined and they were followed up. After a period of 36 months, 28 patients were analyzed and 7 (2 due to medication, 1 due to immigration and 4 due to disability) were dropped out of the study. The EDSS questionnaire was completed for patients in each care period. Data were analyzed using Colomogram Smirnov, Kay Do and Variance analysis statistics. Results: The mean age was 23.67±7.31 and the mean duration of the disease was 6.89±3.47 years. The mean frequency of recurrence of MS before the intervention was 1.94±1.28 and in the first year after the intervention, it was 0.37±0.68, in the second year 0.5±0.63 and in the third year it was reduced 0.32±0.47. 88.9% patients had not progress in EDSS, 75% had no recurrence and 58.2% had no new lesions or an increase in the size of the lesions on MRI II. The frequency of GAD lesions was significantly reduced after the intervention (p=0.03). White blood cells had a decreasing trend in patients (p=0.0001) and two patients were discontinued due to leukopenia and increased liver enzymes, and no severe complication was reported in other patients. Conclusion: Fingolimod was a suitable alternative for the treatment of RRMS. In addition to the high efficacy, relatively acceptable side effects of the study with a larger sample size are essential for a more informed assessment of the benefits and risks of this drug for recurrence.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fingolimod</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple sclerosis reference</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">complications</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">disability</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M Maaref</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M Rezaei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Armaghane Danesh Bimonthly Journal</subfield><subfield code="d">Yasuj University Of Medical Sciences, 2016</subfield><subfield code="g">25(2020), 2, Seite 148-161</subfield><subfield code="w">(DE-627)1760628263</subfield><subfield code="x">17286514</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:148-161</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a67eaf6b9022448ebc34bb6eb8cd29c2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://armaghanj.yums.ac.ir/article-1-2485-en.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-6514</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-6514</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">148-161</subfield></datafield></record></collection>
|
| score |
7.4010277 |